SANGAMO THERAPEUTICS INC
SGMO
SGMO was delisted on the 4th of May, 2026.
105 hedge funds and large institutions have $26.2M invested in SANGAMO THERAPEUTICS INC in 2025 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 26 increasing their positions, 32 reducing their positions, and 20 closing their positions.
3% less call options, than puts
Call options by funds: $535K | Put options by funds: $554K
2.25% less ownership
Funds ownership: 20.75% → 18.5% (-2.2%)
6% less funds holding
Funds holding: 112 → 105 (-7)
10% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 20
19% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 32
38% less capital invested
Capital invested by funds: $42.1M → $26.2M (-$16M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$1.21M |
| 2 |
Two Sigma Advisers
New York
|
+$1.18M |
| 3 |
LM
Luminus Management
Houston,
Texas
|
+$482K |
| 4 |
Jane Street
New York
|
+$380K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$307K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
-$1.9M |
| 2 |
Renaissance Technologies
New York
|
-$929K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$641K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$276K |
| 5 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$269K |
SGMO Hedge Fund Activity: Q4 2025 in Review
105 of the 8,235 institutional investors tracked by Wall St. Rank reported a position in SANGAMO THERAPEUTICS INC (SGMO) for Q4 2025, worth a combined $26.2M — down 38% from $42.1M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of SGMO and 18 opened new positions — a net loss of 2 holders — while 32 trimmed existing stakes and 26 added.
The largest buyer was Two Sigma Investments, adding an estimated $1.21M. The largest seller was GSA Capital Partners, cutting an estimated $1.9M.
- 105 institutional investors held SANGAMO THERAPEUTICS INC (SGMO) as of Q4 2025, down from 112 in Q3 2025.
- Funds reported $26.2M of SANGAMO THERAPEUTICS INC stock for Q4 2025, down 38% quarter-over-quarter.
- 18 funds opened new SANGAMO THERAPEUTICS INC positions in Q4 2025 and 20 closed out, a net change of -2 holders.
- The largest SANGAMO THERAPEUTICS INC buyer in Q4 2025 was Two Sigma Investments, an estimated $1.21M added.
- The largest SANGAMO THERAPEUTICS INC seller in Q4 2025 was GSA Capital Partners, an estimated $1.9M sold.
Based on aggregated 13F filings for Q4 2025.